Oi S, Shibata M, Tominaga J, Honda Y, Shinoda M, Takei F, Tsugane R, Matsuzawa K, Sato O
Department of Neurosurgery, Tokai University, School of Medicine, Isehara, Kanagawa, Japan.
J Neurosurg. 2000 Aug;93(2):245-53. doi: 10.3171/jns.2000.93.2.0245.
OBJECT: This prospective study is based on a consecutive series of 20 patients with pineal region tumors who underwent minimally invasive preferential management. The purpose of this report is to discuss the role of neuroendoscopic procedures in the management of pineal region tumors. METHODS: If the tumor markers alpha-fetoprotein and human chorionic gonadotropin were not detected in serum and there was significant ventricular dilation visualized on neuroimages, neuroendoscopic surgery was first applied for tumor debulking with tissue diagnosis and gross morphological analysis of the tumor and the intraventricular structures, followed by third ventriculostomy. Subsequent procedures were determined on the basis of verified individual tumors. For treatment of germinomas and pineoblastomas, if no tumor dissemination was confirmed by pre-, intra-, or postoperative findings, stereotactic radiotherapy or radiosurgery was performed after one course of chemotherapy with the ICE regimen (isofomid, cisplatin, and etoposide) and followed by two additional courses of chemotherapy. For treatment of malignant germ cell tumors, after extensive surgery, adjuvant chemotherapy with the ICE regimen was performed in three courses in all cases. Then radiotherapy was started using various methods, depending on the evidence of tumor dissemination. For treatment of teratomatous and neuroectodermal tumors other than pineoblastomas, extensive surgical removal was performed. As for adjuvant therapy, if the tumor was a low-grade glioma or if the patient was younger than 5 years of age, postoperative treatment did not include radiotherapy. If the tumor was a malignant teratoma or high-grade glioma, conventional focal radiotherapy was performed, followed by chemotherapy with ICE for 1 year. All but two treated patients had ventriculomegaly. Neuroendoscopic procedures were performed in six of 15 treated patients. Neuroendoscopic biopsy with tumor debulking offered enough material for tissue diagnosis, including immunohistochemical analysis and, in one case, revealed evidence of tumor dissemination undetectable on neuroimaging. With one exception, no shunt was required in any patient undergoing endoscopic third ventriculostomy. Stereotactic radiotherapy was performed in indicated cases. Favorable therapeutic outcomes were obtained in all cases of germinoma and pineoblastoma, with follow-up periods ranging from 24 months to 6.5 years. CONCLUSIONS: Our minimally invasive preferential regimen clarified the precise indication for neuroendoscopic procedures, and the majority of our patients with dilated ventricles and no evidence of tumor markers were treated satisfactorily with effective neuroendoscopic procedures as the initial procedure, avoiding unnecessary craniotomy and radiotherapy and promising excellent therapeutic outcomes. The treatment for malignant pineal region tumors remains a subject for further study.
目的:本前瞻性研究基于连续20例接受微创优先治疗的松果体区肿瘤患者。本报告的目的是探讨神经内镜手术在松果体区肿瘤治疗中的作用。 方法:如果血清中未检测到肿瘤标志物甲胎蛋白和人绒毛膜促性腺激素,且神经影像显示有明显的脑室扩张,则首先应用神经内镜手术进行肿瘤切除,同时进行组织诊断以及对肿瘤和脑室内结构进行大体形态分析,随后行第三脑室造瘘术。后续治疗根据确诊的个体肿瘤情况而定。对于生殖细胞瘤和松果体母细胞瘤的治疗,如果术前、术中或术后检查未证实有肿瘤播散,则在采用ICE方案(异环磷酰胺、顺铂和依托泊苷)进行一个疗程的化疗后,进行立体定向放疗或放射外科治疗,随后再进行两个疗程的化疗。对于恶性生殖细胞肿瘤的治疗,在广泛手术切除后,所有病例均采用ICE方案进行三个疗程的辅助化疗。然后根据肿瘤播散的证据,采用不同方法开始放疗。对于松果体母细胞瘤以外的畸胎瘤和神经外胚层肿瘤,进行广泛的手术切除。至于辅助治疗,如果肿瘤为低级别胶质瘤或患者年龄小于5岁,则术后治疗不包括放疗。如果肿瘤为恶性畸胎瘤或高级别胶质瘤,则进行常规局部放疗,随后采用ICE方案化疗1年。除两名接受治疗的患者外,所有患者均有脑室扩大。15例接受治疗的患者中有6例行神经内镜手术。神经内镜活检及肿瘤切除提供了足够的组织诊断材料,包括免疫组化分析,且有1例显示神经影像未检测到的肿瘤播散证据。除1例例外,接受内镜下第三脑室造瘘术的患者均无需分流。在有指征的病例中进行了立体定向放疗。所有生殖细胞瘤和松果体母细胞瘤病例均获得了良好的治疗效果,随访期为24个月至6.5年。 结论:我们的微创优先治疗方案明确了神经内镜手术的精确指征,大多数脑室扩张且无肿瘤标志物证据的患者以有效的神经内镜手术作为初始治疗方法,治疗效果满意,避免了不必要的开颅手术和放疗,并有望获得优异的治疗效果。恶性松果体区肿瘤的治疗仍有待进一步研究。
Minim Invasive Neurosurg. 2001-6
Zhonghua Wai Ke Za Zhi. 2014-8
J Neurosurg Sci. 2005-9
J Neurosurg. 1998-3
Adv Tech Stand Neurosurg. 2024
Adv Tech Stand Neurosurg. 2023
Biosensors (Basel). 2023-8-14
Childs Nerv Syst. 2023-9
Radiol Case Rep. 2022-6-17
Childs Nerv Syst. 2023-9